Detalhe da pesquisa
1.
Evaluating the Efficacy and Safety of Aflibercept Biosimilar (P041) Compared with Originator Product in Patients with Neovascular Age-Related Macular Degeneration.
Ophthalmol Retina
; 2024 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38428459
2.
Evaluating the efficacy and safety of SpikoGen®, an Advax-CpG55.2-adjuvanted severe acute respiratory syndrome coronavirus 2 spike protein vaccine: a phase 3 randomized placebo-controlled trial.
Clin Microbiol Infect
; 29(2): 215-220, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36096430
3.
The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases.
Int Immunopharmacol
; 102: 108402, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863654
4.
Safety and immunogenicity of SpikoGen®, an Advax-CpG55.2-adjuvanted SARS-CoV-2 spike protein vaccine: a phase 2 randomized placebo-controlled trial in both seropositive and seronegative populations.
Clin Microbiol Infect
; 28(9): 1263-1271, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35436611
5.
A Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis.
J Osteoporos
; 2021: 7584308, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34194720
6.
A randomized phase I pharmacokinetic trial comparing the potential biosimilar adalimumab (CinnoRA®) with the reference product (Humira®) in healthy volunteers.
Expert Opin Investig Drugs
; 29(3): 327-331, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31985294